Search

Displaying results 5101 - 5110 of 7897 in total
  1. Drug

    Olcegepant

    go.drugbank.com/drugs/DB04869
    Investigational

    Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks … Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine.

  2. Drug

    Triazolam

    go.drugbank.com/drugs/DB00897
    ApprovedInvestigational

    Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.

    Products: Triazolam Tab 0.25mg, Triazolam Tab 0.125mg
  3. Drug

    Palifermin

    go.drugbank.com/drugs/DB00039
    ApprovedInvestigational

    Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.[L17933]

  4. Drug

    Ertapenem

    go.drugbank.com/drugs/DB00303
    ApprovedInvestigational

    [A447] Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections. … Ertapenem is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics.[L14339] It was first authorized for use in the US in November 2001 and in Europe in April 2002.

    Products: ERTAPENEM 1G/VIAL POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION INYECTABLE
  5. Drug

    Mepivacaine

    go.drugbank.com/drugs/DB00961
    ApprovedInvestigationalVet approved

    A local anesthetic that is chemically related to bupivacaine but pharmacologically related to lidocaine. It is indicated for infiltration, nerve block, and epidural anesthesia.

    Products: A. T. O. MEPIVACAINE 3% PLAIN. SOLUCION INYECTYABLE
  6. Drug

    Epratuzumab

    go.drugbank.com/drugs/DB04958
    Investigational

    Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). … This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.

  7. Drug

    humanized SMART Anti-IL-12 Antibody

    go.drugbank.com/drugs/DB05848
    Experimental

    IL-12 is a cytokine that may have considerable potential as a target in the therapy of autoimmune diseases. … SMART Anti-IL-12 Antibody was humanized at PDL from a murine anti-IL-12 antibody that was licensed, together with certain intellectual property related to anti-IL-12 therapy, from Hoffmann-La Roche Inc

  8. Drug

    Zomepirac

    go.drugbank.com/drugs/DB04828
    ApprovedWithdrawn

    Zomepirac, formerly marketed as Zomax tablets, was associated with fatal and near-fatal anaphylactoid reactions.

  9. Drug

    R343

    go.drugbank.com/drugs/DB06316
    Investigational

    R343, was investigated in clinical trial NCT01591044 to evaluate its safety and efficacy in patients with mild to moderate asthma.

  10. Drug

    N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine

    go.drugbank.com/drugs/DB13948
    Experimental

    It was discovered in 2014 at the University of Copenhagen. … 25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist.